FAERS Data Shows GLP-1 Drug Skin Reactions Are Less Common Than DPP-4 Inhibitor Skin Reactions
GLP-1 RA cutaneous adverse events (up to 8.16% of cases) were proportionally less common than DPP-4 inhibitor skin reactions (PRR 0.27), with semaglutide having the highest rate and dulaglutide the lowest.
Quick Facts
What This Study Found
Cutaneous AEs reported in up to 8.16% of GLP-1 RA cases; semaglutide highest rate, dulaglutide lowest. PRR 0.27 vs DPP-4 inhibitors indicates proportionally fewer skin events. Exenatide showed increased odds (OR 5.01).
Key Numbers
How They Did This
Analysis of FDA FAERS data (2018-2024) for semaglutide, liraglutide, exenatide, and dulaglutide, with PRR calculation using DPP-4 inhibitors as comparator and logistic regression for predictors.
Why This Research Matters
Skin reactions can affect treatment adherence. Knowing which GLP-1 drugs have better dermatologic profiles helps guide prescribing decisions, especially as indications expand beyond diabetes.
The Bigger Picture
The overall lower skin reaction rate compared to DPP-4 inhibitors is reassuring as GLP-1 drugs expand to new indications including inflammatory skin conditions.
What This Study Doesn't Tell Us
FAERS has inherent reporting biases. Cannot determine causation. Underreporting likely. Denominator (total prescriptions) not available for true incidence calculation.
Questions This Raises
- ?Why does exenatide have higher skin event odds than other GLP-1 drugs?
- ?Should patients with pre-existing skin conditions prefer specific GLP-1 agents?
- ?Do the immunomodulatory properties of GLP-1 drugs actually protect against some skin reactions?
Trust & Context
- Key Stat:
- PRR 0.27 GLP-1 drugs had proportionally 73% fewer skin adverse events compared to DPP-4 inhibitors
- Evidence Grade:
- Large pharmacovigilance database analysis. Useful for signal detection but limited by FAERS reporting biases.
- Study Age:
- Published in 2025 using 2018-2024 FAERS data.
- Original Title:
- Cutaneous Adverse Events Associated With GLP-1 Receptor Agonists: A FAERS Database Analysis From 2018-2024.
- Published In:
- Journal of drugs in dermatology : JDD, 25(1), 11-16 (2026)
- Authors:
- Fat, Marisa N, Johnson, Hayden C, Farberg, Aaron S
- Database ID:
- RPEP-15155
Evidence Hierarchy
Frequently Asked Questions
Do GLP-1 drugs cause skin problems?
Skin reactions are reported in up to 8% of cases, including rash, itching, and hives. However, GLP-1 drugs actually have proportionally fewer skin reactions than DPP-4 inhibitors (another diabetes drug class).
Which GLP-1 drug is safest for skin?
Dulaglutide had the lowest rate of skin reactions, while semaglutide had the highest. Exenatide was an outlier with significantly higher odds of skin events.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15155APA
Fat, Marisa N; Johnson, Hayden C; Farberg, Aaron S. (2026). Cutaneous Adverse Events Associated With GLP-1 Receptor Agonists: A FAERS Database Analysis From 2018-2024.. Journal of drugs in dermatology : JDD, 25(1), 11-16. https://doi.org/10.36849/JDD.9448
MLA
Fat, Marisa N, et al. "Cutaneous Adverse Events Associated With GLP-1 Receptor Agonists: A FAERS Database Analysis From 2018-2024.." Journal of drugs in dermatology : JDD, 2026. https://doi.org/10.36849/JDD.9448
RethinkPeptides
RethinkPeptides Research Database. "Cutaneous Adverse Events Associated With GLP-1 Receptor Agon..." RPEP-15155. Retrieved from https://rethinkpeptides.com/research/fat-2026-cutaneous-adverse-events-associated
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.